Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT06740552
Status
Completed

Conditions

  • Acute Myocardial Infarction (AMI)
  • Multivessel Coronary Artery Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Evolocumab — DRUG
    Evolocumab 140mg every two weeks
  • Lipid Lowering Medication — DRUG
    Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.

Study Details

The goal of this Target Trial Emulation (TTE) study is to evaluate the effect of evolocumab on clinical prognosis in patients with multivessel disease (MVD) following acute myocardial infarction (AMI) who have deferred non-culprit vessel. The main question it aims to answer is: Does evolocumab lower risks of major adverse cardiovascular events (MACE) in patients with deferred non-culprit vessel after AMI?

Key Dates

Start date
Jan 1, 2021
Status verified
Oct 2025
Primary completion
Dec 31, 2024
Completion
Oct 31, 2025

Study Design

Enrollment
1,862 participants (actual)

Arms

  • Arm: TTE cohort
    The TTE cohort is the finally anlyzed population. The participates are enrolled upon meeting the inclusion/exclusion criteria.

Primary Outcome Measure

MACE [ Time Frame: 2 years ]

Related Studies